Aruna Dontabhaktuni

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

Diane Reidy‐Lagunes, Efsevia Vakiani, Marwan Fakih et al. · Journal of Clinical Oncology · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Bart C. Kuenen, Petronella O. Witteveen, Rita Ruijter et al. · Clinical Cancer Research · 2010 · 86 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Measurement of Surface pH of Pharmaceutical Solids: A Critical Evaluation of Indicator Dye-Sorption Method and its Comparison With Slurry pH Method

Madhu Pudipeddi, Erika A. Zannou, Madhav Vasanthavada et al. · Journal of Pharmaceutical Sciences · 2007 · 78 citations

Natural Sciences, Chemistry, Pharmaceutical Analysis +9

Oxidative stress is the master operator of drug and chemically‐induced programmed and unprogrammed cell death: Implications of natural antioxidants<i>in vivo</i>

Sidhartha D. Ray, Tsz Shan Lam, J. A. Rotollo et al. · BioFactors · 2004 · 62 citations

Life Sciences, Biochemistry, Cell Biology +17

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

E. Gabriela Chiorean, Christopher Sweeney, Hagop Youssoufian et al. · Cancer Chemotherapy and Pharmacology · 2014 · 61 citations

Pharmacy, Oncology, Immunotherapy +15